Biology Reference
In-Depth Information
[61] Blazar BR, Taylor PA, Panoskaltsis-Mortari A, Vallera DA. Rapamycin inhibits the
generation of graft-versus-host disease- and graft-versus-leukemia-causing T cells
by interfering with the production of Th1 or Th1 cytotoxic cytokines. J Immunol
1998;160(11):5355-65.
[62] Tawara I, Maeda Y, Sun Y, et al. Combined Th2 cytokine deficiency in donor T cells ag-
gravates experimental acute graft-vs-host disease. Exp Hematol 2008;36(8):988-96.
[63] Nikolic B, Lee S, Bronson RT, Grusby MJ, Sykes M. Th1 and Th2 mediate acute
graft-versus-host disease, each with distinct end-organ targets. J Clin Invest
2000;105(9):1289-98.
[64] Liu J, Anderson BE, Robert ME, et al. Selective T-cell subset ablation demonstrates a
role for T1 and T2 cells in ongoing acute graft-versus-host disease: a model system for
the reversal of disease. Blood 2001;98(12):3367-75.
[65] Murphy WJ, Welniak LA, Taub DD, et al. Differential effects of the absence of interferon-
gamma and IL-4 in acute graft-versus-host disease after allogeneic bone marrow
transplantation in mice. J Clin Invest 1998;102(9):1742-8.
[66] Yi T, Chen Y, Wang L, et al. Reciprocal differentiation and tissue-specific pathogenesis
of Th1, Th2, and Th17 cells in graft-versus-host disease. Blood 2009;114(14):3101-12.
[67] Yu Y, Wang D, Liu C, et al. Prevention of GVHD while sparing GVL effect by tar-
geting Th1 and Th17 transcription factor T-bet and RORgammat in mice. Blood
2011;118(18):5011-20.
[68] Filipovich AH, Weisdorf D, Pavletic S, et al. National Institutes of Health consensus
development project on criteria for clinical trials in chronic graft-versus-host dis-
ease. I. Diagnosis and staging working group report. Biol Blood Marrow Transplant
2005;11(12):945-56.
[69] Chen X, Vodanovic-Jankovic S, Johnson B, Keller M, Komorowski R, Drobyski WR.
Absence of regulatory T-cell control of TH1 and TH17 cells is responsible for the
autoimmune-mediated pathology in chronic graft-versus-host disease. Blood
2007;110(10):3804-13.
[70] Imanguli MM, Swaim WD, League SC, Gress RE, Pavletic SZ, Hakim FT. Increased
T-bet+ cytotoxic effectors and type I interferon-mediated processes in chronic graft-
versus-host disease of the oral mucosa. Blood 2009;113(15):3620-30.
[71] Fowler DH, Kurasawa K, Smith R, Eckhaus MA, Gress RE. Donor CD4-enriched cells of
Th2 cytokine phenotype regulate graft-versus-host disease without impairing alloge-
neic engraftment in sublethally irradiated mice. Blood 1994;84(10):3540-9.
[72] Krenger W, Snyder KM, Byon JC, Falzarano G, Ferrara JL. Polarized type 2 alloreac-
tive CD4+ and CD8+ donor T cells fail to induce experimental acute graft-versus-host
disease. J Immunol 1995;155(2):585-93.
[73] Fowler DH, Breglio J, Nagel G, Eckhaus MA, Gress RE. Allospecific CD8+ Tc1 and Tc2
populations in graft-versus-leukemia effect and graft-versus-host disease. J Immunol
1996;157(11):4811-21.
[74] Jung U, Foley JE, Erdmann AA, Eckhaus MA, Fowler DH. CD3/CD28-costimulated T1
and T2 subsets: differential in vivo allosensitization generates distinct GVT and GVHD
effects. Blood 2003;102(9):3439-46.
[75] Fowler DH. Shared biology of GVHD and GVT effects: potential methods of separation.
Crit Rev Oncol Hematol 2006;57(3):225-44.
[76] Powell JD, Pollizzi KN, Heikamp EB, Horton MR. Regulation of immune responses by
mTOR. Annu Rev Immunol 2012;30:39-68.
[77] Slavik JM, Lim DG, Burakoff SJ, Hafler DA. Uncoupling p70(s6) kinase activation and
proliferation: rapamycin-resistant proliferation of human CD8(+) T lymphocytes. J Im-
munol 2001;166(5):3201-9.
[78] Jung U, Foley JE, Erdmann AA, et al. Ex vivo rapamycin generates Th1/Tc1 or Th2/Tc2
effector T cells with enhanced in vivo function and differential sensitivity to post-trans-
plant rapamycin therapy. Biol Blood Marrow Transplant 2006;12(9):905-18.
[79] Powell JD, Lerner CG, Schwartz RH. Inhibition of cell cycle progression by rapamy-
cin induces T cell clonal anergy even in the presence of costimulation. J Immunol
1999;162(5):2775-84.
[80] Hinrichs CS, Borman ZA, Cassard L, et al. Adoptively transferred effector cells derived
from naive rather than central memory CD8+ T cells mediate superior antitumor im-
munity. Proc Natl Acad Sci U S A 2009;106(41):17469-74.
[81] Foley JE, Jung U, Miera A, et al. Ex vivo rapamycin generates donor Th2 cells that
potently inhibit graft-versus-host disease and graft-versus-tumor effects via an IL-4-
dependent mechanism. J Immunol 2005;175(9):5732-43.
[82] Berger C, Jensen MC, Lansdorp PM, Gough M, Elliott C, Riddell SR. Adoptive transfer
of effector CD8+ T cells derived from central memory cells establishes persistent T cell
memory in primates. J Clin Invest 2008;118(1):294-305.
243
Search WWH ::
Custom Search